

| COVID-19 Vaccines & Administration Codes                                                                                                                                                                       |           |                                                                                                                                                                                                                                                              |                                                                                         |              |                                                       |                          |                                                                  |                                     |               |                                 |                                                                    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|--------------|-------------------------------------------------------|--------------------------|------------------------------------------------------------------|-------------------------------------|---------------|---------------------------------|--------------------------------------------------------------------|
| Revised: April 1, 2023                                                                                                                                                                                         |           |                                                                                                                                                                                                                                                              |                                                                                         |              |                                                       |                          |                                                                  |                                     |               |                                 |                                                                    |
| ***Submit claim for administration fee with the appropriate vaccine CPT Code. The administration Code must appear on the detail line prior the vaccine code. (See NOTE Section for additional instructions)*** |           |                                                                                                                                                                                                                                                              |                                                                                         |              |                                                       |                          |                                                                  |                                     |               |                                 |                                                                    |
| #                                                                                                                                                                                                              | CPT HCPCS | Vaccine Code Description, Dose                                                                                                                                                                                                                               | Vaccine Administration Code(s)                                                          | Labeler Name | Drug Name                                             | Patient's Age            | NDC                                                              | Max Allow                           | Max Units/Day | GAMMIS Effective Date (Vaccine) | NOTE                                                               |
| 1                                                                                                                                                                                                              | 91300     | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use                                         | 0001A (First Dose)<br>0002A (Second Dose)<br>0003A (Third Dose)<br>0004A (Booster Dose) | Pfizer, Inc. | PFIZER-BIONTECH COVID-19 VACC 30MCG/0.3ML Suspension  | 12 Years & Older         | 59267-1000-01<br>59267-1000-02<br>59267-1000-03                  | \$0.00 - Vaccine<br>\$40.00 - Admin | 1             | 12/11/2020                      | Report 91300 with administration codes 0001A, 0002A, 0003A, 0004A  |
| 2                                                                                                                                                                                                              | 91301     | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use                                                               | 0011A (First Dose)<br>0012A (Second Dose)<br>0013A (Third Dose)                         | Moderna, Inc | MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution        | 12 Years & Older         | 80777-0273-10<br>80777-0273-15<br>80777-0273-98<br>80777-0273-99 | \$0.00 - Vaccine<br>\$40.00 - Admin | 1             | 12/18/2020                      | Report 91301 with administration codes 0011A, 0012A, 0013A         |
| 3                                                                                                                                                                                                              | 91303     | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use    | 0031A (Single Dose)<br>0034A (Booster Dose)                                             | Janssen      | JANSSEN COVID-19 VACCINE 0.5ML Suspension             | 18 Years & Older         | 59676-0580-05<br>59676-0580-15                                   | \$0.00 - Vaccine<br>\$40.00 - Admin | 1             | 2/27/2021                       | Report 91303 with administration codes 0031A, 0034A                |
| 4                                                                                                                                                                                                              | 91304     | severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use                          | 0041A (1st Dose)<br>0042A (2nd Dose)                                                    | Novavax      | Novavax Covid-19 Vaccine, Adjuvanted                  | 12 Years & Older         | 80631-1000-01                                                    | \$0.00 - Vaccine<br>\$40.00 - Admin | 1             | 7/13/2022                       | Report 91304 with administration codes 0041A, 0042A, 0044A         |
|                                                                                                                                                                                                                |           |                                                                                                                                                                                                                                                              | 0044A (Bosster Dose)                                                                    |              |                                                       | 18 Years & Older         | 80631-1000-01                                                    |                                     |               | 10/19/2022                      |                                                                    |
| 5                                                                                                                                                                                                              | 91305     | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use                                     | 0051A (First Dose)<br>0052A (Second Dose)<br>0053A (Third Dose)<br>0054A (Booster Dose) | Pfizer, Inc. | PFIZER-BIONT COVID-19 VAC-TRIS 30MCG/0.3ML Suspension | 12 Years & Older         | 59267-1025-01<br>59267-1025-02<br>59267-1025-03<br>59267-1025-04 | \$0.00 - Vaccine<br>\$40.00 - Admin | 1             | 11/1/2021                       | Report 91305 with administration codes 0051A, 0052A, 0053A, 0054A  |
| 6                                                                                                                                                                                                              | 91306     | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use                                                              | 0064A (Booster Dose)                                                                    | Moderna      | MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution        | 18 Years & Older         | 80777-0273-10<br>80777-0273-15<br>80777-0273-98<br>80777-0273-99 | \$0.00 - Vaccine<br>\$40.00 - Admin | 1             | 10/20/2021                      | Report 91306 with administration code 0064A                        |
| 7                                                                                                                                                                                                              | 91307     | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use              | 0071A (First Dose)<br>0072A (Second Dose)<br>0073A (Third Dose)<br>0074A (Booster Dose) | Pfizer, Inc. | PFIZER COVID-19 VAC-TRIS 5-11Y 10MCG/0.2ML Suspension | 5-11 Years Old           | 59267-1055-01<br>59267-1055-02<br>59267-1055-04                  | \$0.00 - Vaccine<br>\$40.00 - Admin | 1             | 10/29/2021                      | Report 91307 with administration codes 0071A, 0072A                |
| 8                                                                                                                                                                                                              | 91308     | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use               | 0081A (1st Dose)<br>0082A (2nd Dose)<br>0083A (3rd Dose)                                | Pfizer, Inc. | Pfizer-BioNTech Covid-19 Pediatric Vaccine            | 6 Months - 4 Years       | 59267-0078-01<br>59267-0078-04                                   | \$0.00 - Vaccine<br>\$40.00 - Admin | 1             | 6/17/2022                       | Report 91308 with administration codes 0081A, 0082A, 0083A         |
| 9                                                                                                                                                                                                              | 91309     | Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use                                                                | 0091A (1st Dose)<br>0092A (2nd Dose)<br>0093A (3rd Dose)                                | Moderna, Inc | Moderna COVID-19 Vaccine                              | 6 - 11 Years             | 80777-0275-05                                                    | \$0.00 - Vaccine<br>\$40.00 - Admin | 1             | 6/17/2022                       | Report 91309 with administration codes 0091A, 0092A, 0093A, 0094A  |
|                                                                                                                                                                                                                |           |                                                                                                                                                                                                                                                              | 0094A (Booster)                                                                         |              |                                                       | 18 Years & older         |                                                                  |                                     |               | 3/29/2022                       |                                                                    |
| 10                                                                                                                                                                                                             | 91311     | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use                                                              | 0111A (1st Dose)<br>0112A (2nd Dose)<br>0113A (3rd Dose)                                | Moderna, Inc | Moderna COVID -19 Vaccine                             | 6 Months - 5 Years       | 80777 -0279 -05                                                  | \$0.00 - Vaccine<br>\$40.00 - Admin | 1             | 6/17/2022                       | Report 91311 with administration codes 0111A, 0112A, 0113A         |
| 11                                                                                                                                                                                                             | 91312     | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, trissucrose formulation, for intramuscular use                             | 0124A (Booster)                                                                         | Pfizer, Inc. | Pfizer-BioNTech COVID-19 Bivalent                     | 12 Years & older         | 59267-0304-01<br>59267-1404-01                                   | \$0.00 - Vaccine<br>\$40.00 - Admin | 1             | 8/31/2022                       | Report 91312 with administration code 00124A                       |
| 12                                                                                                                                                                                                             | 91313     | Severe acute respiratory syndrome coronavirus 2 (SARS -CoV -2) (coronavirus disease [COVID -19]) vaccine, mRNA -LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use                                                 | 0134A (Booster)                                                                         | Moderna, Inc | Moderna COVID-19 Vaccine, Bivalent Product            | 18 Years & older         | 80777 -0282 -05                                                  | \$0.00 - Vaccine<br>\$40.00 - Admin | 1             | 8/31/2022                       | Report 91313 with administration code 00134A                       |
| 13                                                                                                                                                                                                             | 91314     | Severe acute respiratory syndrome coronavirus 2 (SARS -CoV -2) (coronavirus disease [COVID -19]) vaccine, mRNA -LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use                                                | 0144A (Booster)                                                                         | Moderna, Inc | Moderna COVID -19 Vaccine, Bivalent                   | 6 - 11 Years             | 80777 -0282 -05                                                  | \$0.00 - Vaccine<br>\$40.00 - Admin | 1             | 8/31/2022                       | Report 91314 with administration code 00144A                       |
| 14                                                                                                                                                                                                             | 91315     | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use     | 0154A (Booster)                                                                         | Pfizer, Inc. | Pfizer-BioNTech COVID-19 Bivale                       | 5 - 11 Years             | 59267-0565-01                                                    | \$0.00 - Vaccine<br>\$40.00 - Admin | 1             | 8/31/2002                       | Report 91315 with administration code 00154A                       |
| 15                                                                                                                                                                                                             | 91316     | Severe acute respiratory syndrome coronavirus 2 (SARS -CoV -2) (coronavirus disease [COVID -19]) vaccine, mRNA -LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use                                                 | 0164A (Booster)                                                                         | Moderna, Inc | Moderna COVID -19 Vaccine, Bivalent                   | 6 months through 5 years | 80777 -0283 -02                                                  | \$0.00 - Vaccine<br>\$40.00 - Admin | 1             | 12/8/2022                       | Report 91316 with administration code 00164A                       |
| 16                                                                                                                                                                                                             | 91317     | Severe acute respiratory syndrome coronavirus 2 (SARS -CoV -2) (coronavirus disease [COVID -19]) vaccine, mRNA -LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris -sucrose formulation, for intramuscular use | 00173A (3rd Dose)<br>00174A (Booster)                                                   | Pfizer, Inc. | Pfizer -BioNTech COVID -19 Bivalen                    | 6 months through 4 years | 59267 -0609 -01                                                  | \$0.00 - Vaccine<br>\$40.00 - Admin | 1             | 12/8/2022                       | Report 91317 with administration code 00173A & 00174A              |
| 17                                                                                                                                                                                                             | M0201     | Covid-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home                                                             | N/A                                                                                     | N/A          | N/A                                                   | n                        | N/A                                                              | \$35.50                             | 1             | 6/8/2021                        | Report M0201 with any combination of vaccine & administration code |

| COVID-19 Monoclonal Antibodies & Administration Codes                                                                                                                                                                                              |       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |              |                                   |                                                 |           |               |                                       |                                                           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----------------------------------|-------------------------------------------------|-----------|---------------|---------------------------------------|-----------------------------------------------------------|
| Revised: April 1, 2023                                                                                                                                                                                                                             |       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |              |                                   |                                                 |           |               |                                       |                                                           |
| ***Submit claim for administration fee with the appropriate Monoclonal Antibody HCPCS. The administration code must appear on the claim detail line prior the code for the Monoclonal Antibodies (See NOTE Section for additional instructions)*** |       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |              |                                   |                                                 |           |               |                                       |                                                           |
| #                                                                                                                                                                                                                                                  | HCPCS | CPT/HCPCS Name, Description, Dose                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Labeler Name | Drug Name                         | NDC                                             | Max Allow | Max Units/Day | GAMMIS Effective Date (Monoclonal...) | NOTE                                                      |
| 1                                                                                                                                                                                                                                                  | Q0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg                                                                                                                                                                                                           | Astra Zeneca | EVUSHELD 150-150MG/1.5ML Solution | 00310-1061-01<br>00310-7442-02<br>00310-8895-01 | \$0.00    | 1             | 12/8/2021                             | Report Q0220 with administration codes M0220, M0221       |
| 2                                                                                                                                                                                                                                                  | Q0221 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg                                                                                                                                                                                                           | AstraZeneca  | Tixagev and cilgav, 600mg         | 00310-1061-01<br>00310-7442-02<br>00310-8895-01 | \$0.00    | 1             | 2/24/2022                             | Report Q0221 with administration codes M0220, M0221       |
| 3                                                                                                                                                                                                                                                  | M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring                                                                                                                                                            | Astra Zeneca | N/A                               | N/A                                             | \$120.00  | 1             | 12/8/2021                             | Report M0220 with Q0220 & Q0221                           |
| 4                                                                                                                                                                                                                                                  | M0221 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency | Astra Zeneca | N/A                               | N/A                                             | \$200.00  | 1             | 12/8/2021                             | Report M0221 with Q0220 & Q0221 for home administration   |
| 5                                                                                                                                                                                                                                                  | Q0222 | Bebtelovimab, 175 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Eli Lilly    | BEBTELOVIMA                       | 00002-7589-01                                   | \$0.00    | 1             | 2/11/2022                             | Report Q0222 with administration codes M0222, M0223       |
| 6                                                                                                                                                                                                                                                  | M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Eli Lilly    | N/A                               | N/A                                             | \$280.00  | 1             | 2/11/2022                             | Report M0222 with Q0222                                   |
| 7                                                                                                                                                                                                                                                  | M0223 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency                                                                                                                                                                                                                                                                                                                                                                                                                                       | Eli Lilly    | N/A                               | N/A                                             | \$440.00  | 1             | 2/11/2022                             | Report M0223 with Q0222                                   |
| 8                                                                                                                                                                                                                                                  | Q0240 | Casirivimab and Imdevimab, 600 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Regeneron    | CASIRIVIMAB 300MG/2.5ML Solution  | 61755-0026-00                                   | \$0.00    | 1             | 7/30/2021                             | Report Q0240 with administration codes M0240, M0241       |
|                                                                                                                                                                                                                                                    | Q0240 | Casirivimab and Imdevimab, 600 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Regeneron    | CASIRIVIMAB 300MG/2.5ML Solution  | 61755-0026-01                                   | \$0.00    | 1             | 7/30/2021                             | Report Q0240 with administration codes M0240, M0241       |
|                                                                                                                                                                                                                                                    | Q0240 | Casirivimab and Imdevimab, 600 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Regeneron    | IMDEVIMAB 300MG/2.5ML Solution    | 61755-0027-00                                   | \$0.00    | 1             | 7/30/2021                             | Report Q0240 with administration codes M0240, M0241       |
|                                                                                                                                                                                                                                                    | Q0240 | Casirivimab and Imdevimab, 600 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Regeneron    | IMDEVIMAB 300MG/2.5ML Solution    | 61755-0027-01                                   | \$0.00    | 1             | 7/30/2021                             | Report Q0240 with administration codes M0240, M0241       |
| 9                                                                                                                                                                                                                                                  | M0240 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Regeneron    | N/A                               | N/A                                             | \$360.00  | 1             | 6/8/2021                              | Report M0240 with Q0240                                   |
| 10                                                                                                                                                                                                                                                 | M0241 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses                                                                                                                                                                                                                                                                                                                                                            | Regeneron    | N/A                               | N/A                                             | \$600.00  | 1             | 7/30/2021                             | Report M0241 with Q0240 for home/residence administration |
| 11                                                                                                                                                                                                                                                 | Q0243 | Casirivimab and Imdevimab, 2400 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Regeneron    | CASIRIVIMAB 1200MG Solution       | 61755-0024-01                                   | \$0.00    | 1             | 12/1/2020                             | Report Q0243 with administration codes M0243, M0244       |
|                                                                                                                                                                                                                                                    | Q0243 | Casirivimab and Imdevimab, 2400 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Regeneron    | IMDEVIMAB 1200MG Solution         | 61755-0025-01                                   | \$0.00    | 1             | 12/1/2020                             | Report Q0243 with administration codes M0243, M0244       |
|                                                                                                                                                                                                                                                    | Q0243 | Casirivimab and Imdevimab, 2400 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Regeneron    | CASIRIVIMAB 300MG/2.5ML Solution  | 61755-0026-01                                   | \$0.00    | 1             | 12/1/2020                             | Report Q0243 with administration codes M0243, M0244       |
|                                                                                                                                                                                                                                                    | Q0243 | Casirivimab and Imdevimab, 2400 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Regeneron    | IMDEVIMAB 300MG/2.5ML Solution    | 61755-0027-01                                   | \$0.00    | 1             | 12/1/2020                             | Report Q0243 with administration codes M0243, M0244       |
|                                                                                                                                                                                                                                                    | Q0243 | Casirivimab and Imdevimab, 2400 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Regeneron    | REGEN-COV 1200MG/1200MG Solution  | 61755-0035-02                                   | \$0.00    | 1             | 12/1/2020                             | Report Q0243 with administration codes M0243, M0244       |
|                                                                                                                                                                                                                                                    | Q0243 | Casirivimab and Imdevimab, 2400 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Regeneron    | REGEN-COV 1200MG/1200MG Solution  | 61755-0036-08                                   | \$0.00    | 1             | 12/1/2020                             | Report Q0243 with administration codes M0243, M0244       |

| COVID-19 Monoclonal Antibodies & Administration Codes                                                                                                                                                                                              |       |                                                                                                                                                                                                                                                                                                                                                                                      |           |                                      |               |          |     |           |                                                                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------------------|---------------|----------|-----|-----------|----------------------------------------------------------------------------|
| Revised: April 1, 2023                                                                                                                                                                                                                             |       |                                                                                                                                                                                                                                                                                                                                                                                      |           |                                      |               |          |     |           |                                                                            |
| ***Submit claim for administration fee with the appropriate Monoclonal Antibody HCPCS. The administration code must appear on the claim detail line prior the code for the Monoclonal Antibodies (See NOTE Section for additional instructions)*** |       |                                                                                                                                                                                                                                                                                                                                                                                      |           |                                      |               |          |     |           |                                                                            |
|                                                                                                                                                                                                                                                    | Q0243 | Casirivimab and Imdevimab, 2400 mg                                                                                                                                                                                                                                                                                                                                                   | Regeneron | REGEN-COV 1200MG/1200MG Solution     | 61755-0037-05 | \$0.00   | 1   | 12/1/2020 | Report Q0243 with administration codes M0243, M0244                        |
|                                                                                                                                                                                                                                                    | Q0243 | Casirivimab and Imdevimab, 2400 mg                                                                                                                                                                                                                                                                                                                                                   | Regeneron | REGEN-COV 1200MG/1200MG Solution     | 61755-0038-05 | \$0.00   | 1   | 12/1/2020 | Report Q0243 with administration codes M0243, M0244                        |
|                                                                                                                                                                                                                                                    | Q0243 | Casirivimab and Imdevimab, 2400 mg                                                                                                                                                                                                                                                                                                                                                   | Regeneron | REGEN-COV 600-600MG/10ML Solution    | 61755-0039-01 | \$0.00   | 1   | 12/1/2020 | Report Q0243 with administration codes M0243, M0244                        |
|                                                                                                                                                                                                                                                    | Q0243 | Casirivimab and Imdevimab, 2400 mg                                                                                                                                                                                                                                                                                                                                                   | Regeneron | REGEN-COV 120MG/ML;120MG/ML Solution | 61755-0042-02 | \$0.00   | 1   | 12/1/2020 | Report Q0243 with administration codes M0243, M0244                        |
|                                                                                                                                                                                                                                                    | Q0243 | Casirivimab and Imdevimab, 2400 mg                                                                                                                                                                                                                                                                                                                                                   | Regeneron | REGEN-COV 120MG/ML;120MG/ML Solution | 61755-0045-02 | \$0.00   | 1   | 12/1/2020 | Report Q0243 with administration codes M0243, M0244                        |
| 12                                                                                                                                                                                                                                                 | Q0244 | Casirivimab and Imdevimab, 1200 mg                                                                                                                                                                                                                                                                                                                                                   | Regeneron | CASIRIVIMAB 300MG/2.5ML Solution     | 61755-0026-01 | \$0.00   | 1   | 6/3/2021  | Report Q0244 with administration codes M0243, M0244                        |
|                                                                                                                                                                                                                                                    | Q0244 | Casirivimab and Imdevimab, 1200 mg                                                                                                                                                                                                                                                                                                                                                   | Regeneron | IMDEVIMAB 300MG/2.5ML Solution       | 61755-0027-01 | \$0.00   | 1   | 6/3/2021  | Report Q0244 with administration codes M0243, M0244                        |
|                                                                                                                                                                                                                                                    | Q0244 | Casirivimab and Imdevimab, 1200 mg                                                                                                                                                                                                                                                                                                                                                   | Regeneron | REGEN-COV 600-600MG/10ML Solution    | 61755-0039-01 | \$0.00   | 1   | 6/3/2021  | Report Q0244 with administration codes M0243, M0244                        |
|                                                                                                                                                                                                                                                    | Q0244 | Casirivimab and Imdevimab, 1200 mg                                                                                                                                                                                                                                                                                                                                                   | Regeneron | REGEN-COV 120MG/ML;120MG/ML Solution | 61755-0042-02 | \$0.00   | 1   | 6/3/2021  | Report Q0244 with administration codes M0243, M0244                        |
|                                                                                                                                                                                                                                                    | Q0244 | Casirivimab and Imdevimab, 1200 mg                                                                                                                                                                                                                                                                                                                                                   | Regeneron | REGEN-COV 120MG/ML;120MG/ML Solution | 61755-0045-02 | \$0.00   | 1   | 6/3/2021  | Report Q0244 with administration codes M0243, M0244                        |
| 13                                                                                                                                                                                                                                                 | M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring                                                                                                                                                                                                                                         | Regeneron | N/A                                  | N/A           | \$360.00 | 1   | 12/1/2020 | Report M0243 with Q0243/Q0244                                              |
| 14                                                                                                                                                                                                                                                 | M0244 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency                                                                              | Regeneron | N/A                                  | N/A           | \$600.00 | 1   | 5/6/2021  | Report M0244 with Q0243 as well as Q0244 for home/residence administration |
| 15                                                                                                                                                                                                                                                 | Q0245 | Bamlanivimab and Etesevimab, 2100 mg                                                                                                                                                                                                                                                                                                                                                 | Eli Lilly | BAMLANIVIMAB 700MG/20ML Solution     | 00002-7910-01 | \$0.00   | 1   | 2/9/2021  | Report Q0245 with administration codes M0245, M0246                        |
|                                                                                                                                                                                                                                                    | Q0245 | Bamlanivimab and Etesevimab, 2100 mg                                                                                                                                                                                                                                                                                                                                                 | Eli Lilly | ETESEVIMAB 35MG/ML Solution          | 00002-7950-01 | \$0.00   | 1   | 2/9/2021  | Report Q0245 with administration codes M0245, M0246                        |
| 16                                                                                                                                                                                                                                                 | M0245 | intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring                                                                                                                                                                                                                                                                              | Eli Lilly | N/A                                  | N/A           | \$360.00 | 1   | 2/9/2021  | Report M0245 with Q0245                                                    |
| 17                                                                                                                                                                                                                                                 | M0246 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency                                                                                                                   | Eli Lilly | N/A                                  | N/A           | \$600.00 |     | 5/6/2021  | Report M0246 with Q0245 for home/residence administration                  |
| 18                                                                                                                                                                                                                                                 | Q0247 | Sotrovimab, 500 mg                                                                                                                                                                                                                                                                                                                                                                   | GSK       | SOTROVIMAB 500MG/8ML Solution        | 00173-0901-86 | \$0.00   | 1   | 5/26/2021 | Report Q0247 with administration codes M0247, M0248                        |
| 19                                                                                                                                                                                                                                                 | M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring                                                                                                                                                                                                                                                                                               | GSK       | N/A                                  | N/A           | \$360.00 |     | 5/26/2021 | Report M0247 with Q0247                                                    |
| 20                                                                                                                                                                                                                                                 | M0248 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency                                                                                                                                    | GSK       | N/A                                  | N/A           | \$600.00 |     | 5/26/2021 | Report M0248 with Q0247 for home/residence administration                  |
| 21                                                                                                                                                                                                                                                 | Q0249 | Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg                                                                                | Genentech | ACTEMRA 20MG/ML Solution             | 50242-0135-01 | \$6.57   | 800 | 6/24/2021 | Report Q0249 with administration codes M0249, M0250                        |
|                                                                                                                                                                                                                                                    | Q0249 | Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg                                                                                | Genentech | ACTEMRA 200MG/10ML Solution          | 50242-0136-01 | \$6.57   | 800 | 6/24/2021 | Report Q0249 with administration codes M0249, M0250                        |
|                                                                                                                                                                                                                                                    | Q0249 | Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg                                                                                | Genentech | ACTEMRA 400MG/20ML Solution          | 50242-0137-01 | \$6.57   | 800 | 6/24/2021 | Report Q0249 with administration codes M0249, M0250                        |
| 22                                                                                                                                                                                                                                                 | M0249 | Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, <b>first dose</b>  | Genentech | N/A                                  | N/A           | \$360.00 | 1   | 6/24/2021 | Report M0249 with Q0294 - 1st dose                                         |
| 23                                                                                                                                                                                                                                                 | M0250 | Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, <b>second dose</b> | Genentech | N/A                                  | N/A           | \$360.00 | 1   | 6/24/2021 | Report M0250 with Q0294 - 2nd dose                                         |